Corrigendum to “Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARSCoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study” [Life Sci. 253 (2020) 117592]

Detalles Bibliográficos
Autor principal: Elfiky, Abdo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957227/
https://www.ncbi.nlm.nih.gov/pubmed/32863005
http://dx.doi.org/10.1016/j.lfs.2020.118350
_version_ 1783664608543768576
author Elfiky, Abdo A.
author_facet Elfiky, Abdo A.
author_sort Elfiky, Abdo A.
collection PubMed
description
format Online
Article
Text
id pubmed-7957227
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-79572272021-03-15 Corrigendum to “Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARSCoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study” [Life Sci. 253 (2020) 117592] Elfiky, Abdo A. Life Sci Corrigendum Elsevier Inc. 2020-10-01 2020-08-28 /pmc/articles/PMC7957227/ /pubmed/32863005 http://dx.doi.org/10.1016/j.lfs.2020.118350 Text en © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Corrigendum
Elfiky, Abdo A.
Corrigendum to “Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARSCoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study” [Life Sci. 253 (2020) 117592]
title Corrigendum to “Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARSCoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study” [Life Sci. 253 (2020) 117592]
title_full Corrigendum to “Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARSCoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study” [Life Sci. 253 (2020) 117592]
title_fullStr Corrigendum to “Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARSCoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study” [Life Sci. 253 (2020) 117592]
title_full_unstemmed Corrigendum to “Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARSCoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study” [Life Sci. 253 (2020) 117592]
title_short Corrigendum to “Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARSCoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study” [Life Sci. 253 (2020) 117592]
title_sort corrigendum to “ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against sarscov-2 rna dependent rna polymerase (rdrp): a molecular docking study” [life sci. 253 (2020) 117592]
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957227/
https://www.ncbi.nlm.nih.gov/pubmed/32863005
http://dx.doi.org/10.1016/j.lfs.2020.118350
work_keys_str_mv AT elfikyabdoa corrigendumtoribavirinremdesivirsofosbuvirgalidesivirandtenofoviragainstsarscov2rnadependentrnapolymeraserdrpamoleculardockingstudylifesci2532020117592

Ejemplares similares